DPRO Draganfly Inc

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of December 2024

 

Commission File Number: 001-40688

 

DRAGANFLY INC.

(Translation of registrant’s name into English)

 

235 103^rd St. E.

Saskatoon, Saskatchewan S7N 1Y8

Canada

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

☒ Form 20-F

☐ Form 40-F

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Draganfly Inc.
	(Registrant)
Date: December 18, 2024	By:	/s/ Paul Sun
	Name:	Paul Sun
	Title:	Chief Financial Officer

 

 

Form 6-K Exhibit Index

 

Exhibit Number		Document Description
99.1		Press Release of the Registrant dated December 18, 2024.

 

 

Exhibit 99.1

 

 

Draganfly Completes First Proof-of-Concept Flights in Drone Delivery Research Project for Mass General Brigham

 

Draganfly’s medical drone delivery infrastructure offers new model for future improvement in service time for Home Hospital care

 

Boston, MA. December 18, 2024 – Draganfly Inc.(NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, today announced the successful completion of initial flights as part of a proof-of-concept, research-and-development drone delivery project for Mass General Brigham (MGB) Home Hospital.

 

This initial phase involved collaborating with MGB and regulators to evaluate and map potential routes as well as complete test flights that included takeoff and landing within hospital infrastructure. These test flights did not contribute to care delivery. This initiative aims to demonstrate how drone deliveries could ensure timely access to critical medical supplies or laboratory samples, thereby minimizing traditional logistical delays.

 

Phase One of the project focuses on the greater Boston metropolitan area to identify how Draganfly’s proprietary drone technology addresses healthcare logistics challenges by reducing delays caused by traffic congestion and outdated delivery methods.

 

“This is a first step toward our vision of someday delivering high-quality healthcare directly to patients’ homes in a more timely and cost-effective manner,” said Dr. David Levine, MD, MPH, MA, Clinical Director of Research & Development at Mass General Brigham Healthcare at Home.

 

“We are thrilled to see the progress of our drone delivery services with Mass General Brigham. Draganfly’s hope is to establish a transformation in how healthcare providers manage logistics, enabling faster, more reliable delivery of essential supplies that directly benefits patients and care providers alike,” commented Cameron Chell, CEO of Draganfly.

 

Draganfly also participated in the World Medical Innovation Forum, an annual event run by Mass General Brigham that focuses on the latest advancements in medical technology and healthcare innovations. The Forum, which ran from September 23-25 in Boston, MA, attracted healthcare professionals and leaders in medical research and development to discuss and explore new ways to improve patient care and treatment options. Draganfly displayed various technologies used in the medical delivery project during the event.

 

About Draganfly

 

Draganfly Inc. is the creator of quality, cutting-edge drone solutions, software, and AI systems that revolutionize how organizations operate and serve their stakeholders. With over 24 years of innovation, Draganfly is recognized as a leader in the public safety, agriculture, industrial inspections, security, mapping, and surveying markets. The Company’s commitment to ingenuity and first-class services drives its goal to save time, money, and lives across the globe.

 

For more information on Draganfly, please visit Draganfly’s website. For additional investor information, visit:

 

	●	The CSE Listing
	●	NASDAQ Listing
	●	Frankfurt Listing

 

Media Contact Erika Racicot Email: media@draganfly.com

 

Company Contact Email: info@draganfly.com

 

Forward-Looking Statements

 

This release contains certain “forward looking statements” and certain “forward-looking ‎‎‎‎information” as ‎‎‎‎defined under applicable securities laws. Forward-looking statements ‎‎‎‎and information can ‎‎‎‎generally be identified by the use of forward-looking terminology such as ‎‎‎‎‎”may”, “will”, “expect”, “intend”, ‎‎‎‎‎”estimate”, “anticipate”, “believe”, “continue”, “plans” or similar ‎‎‎‎terminology. Forward-looking statements ‎‎‎‎and information are based on forecasts of future ‎‎‎‎results, estimates of amounts not yet determinable and ‎‎‎‎assumptions that, while believed by ‎‎‎‎management to be reasonable, are inherently subject to significant ‎‎‎‎business, economic and ‎‎‎‎competitive uncertainties and contingencies. Forward-looking statements ‎‎‎‎include, but are not ‎‎‎‎limited to, statements with respect to the ability of drones to address healthcare logistics challenges by reducing delays caused by traffic congestion and outdated delivery methods. Forward-‎‎‎‎looking statements and information are subject to various ‎known ‎‎and unknown risks and ‎‎‎‎‎uncertainties, many of which are beyond the ability of the Company to ‎control or ‎‎predict, that ‎‎‎‎may cause ‎the Company’s actual results, performance or achievements to be ‎materially ‎‎different ‎‎‎‎from those ‎expressed or implied thereby, and are developed based on assumptions ‎about ‎‎such ‎‎‎‎risks, uncertainties ‎and other factors set out here in, including but not limited to: the potential ‎‎‎‎‎‎‎impact of epidemics, ‎pandemics or other public health crises, including the ‎COVID-19 pandemic, on the Company’s business, operations and financial ‎‎‎‎condition; the ‎‎‎successful integration of ‎technology; the inherent risks involved in the general ‎‎‎‎securities markets; ‎‎‎uncertainties relating to the ‎availability and costs of financing needed in the ‎‎‎‎future; the inherent ‎‎‎uncertainty of cost estimates; the ‎potential for unexpected costs and ‎‎‎‎expenses, currency ‎‎‎fluctuations; regulatory restrictions; and liability, ‎competition, loss of key ‎‎‎‎employees and other related risks ‎‎‎and uncertainties disclosed under the ‎heading “Risk Factors” ‎‎‎‎in the Company’s most recent filings filed ‎‎‎with securities regulators in Canada on ‎the SEDAR ‎‎‎‎website at www.sedar.com and with the United States Securities and Exchange Commission (the “SEC”) on EDGAR through the SEC’s website at www.sec.gov. The Company undertakes ‎‎‎no obligation to update forward-‎looking ‎‎‎‎information except as required by applicable law. Such forward-‎‎‎looking information represents ‎‎‎‎‎managements’ best judgment based on information currently available. ‎‎‎No forward-looking ‎‎‎‎statement ‎can be guaranteed and actual future results may vary materially. ‎‎‎Accordingly, readers ‎‎‎‎are advised not to ‎place undue reliance on forward-looking statements or ‎‎‎information.‎

 

 

 

---